Plant-Powered hope: diet may slow prostate cancer

NCT ID NCT07220499

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating a whole food plant-based diet for six months can help men with prostate cancer whose PSA levels are rising. Eleven men attended cooking classes and ate mostly plants. Researchers measured changes in PSA, cholesterol, blood sugar, and inflammation. The goal was to see if diet could improve cancer outcomes and reduce treatment risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Nov 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 99 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males 45-99 years of age * Histologically or cytologically confirmed adenocarcinoma of the prostate * Increasing PSA on at least 2 sequential tests not more than 6 months apart. * Eastern Cooperative Oncology Group Performance Status Scale of 0 to 2 * Adequate organ and marrow function, based upon meeting all of the following laboratory criteria: * White blood cell count ≥ 2500/mm3 (≥ 2.5 GI/L) * Platelets ≥ 50,000/mm3 (≥ 100 GI/L) without transfusion * Hemoglobin ≥ 9 g/dL (≥ 90 g/L) * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin ≤ 2x upper limit of normal (or for subjects with Gilbert's syndrome direct bilirubin WNL) Serum albumin ≥ 2.8 g/dl * Willingness and ability to comply with all study-related procedures * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document Exclusion Criteria: * Nut or legume allergy * Currently consuming a vegetarian or vegan diet * Concurrent participation in other nutrition or weight loss programs * Expected changes in exercise patterns during the study period * Active prostatitis * Insulin-dependent or requiring diabetes mellitus * Expected changes in chronic medications, including statins or oral diabetes medication during the study period (including a change in medication dosage) * Expected radiation, chemotherapy, bone resorptive agents or anti-androgen within 2 months of beginning the diet intervention * Known history of electrolyte imbalance or micronutrient deficiency, e.g., magnesium, cobalamin * Ongoing use of warfarin anticoagulants * Diagnosed, active inflammatory bowel disease * Alcohol and/or drug abuse * Psychiatric illnesses or social situations that would limit compliance with study requirements including the inability or lack of equipment to perform basic cooking tasks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pacific Cancer Care

    Monterey, California, 93940, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.